1-20 of 32
David R. Gandara
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Phase II Study of Docetaxel and Trametinib in Patients with KRAS Mutation Positive Recurrent Non–Small Cell Lung Cancer (NSCLC; SWOG S1507, NCT-02642042)

Shirish M. Gadgeel, Jieling Miao, Jonathan W. Riess, James Moon, Philip C. Mack, Gregory J. Gerstner, Timothy F. Burns, Asma Taj, Wallace L. Akerley, III, Konstantin H. Dragnev, Noel Laudi, Mary W. Redman, Jhanelle E. Gray, David R. Gandara, Karen Kelly
Journal: Clinical Cancer Research
Clin Cancer Res (2023) 29 (18): 3641–3649.
https://doi.org/10.1158/1078-0432.CCR-22-3947
Published: 15 September 2023
View article titled, Phase II Study of Docetaxel and Trametinib in Patients with <em>KRAS</em> Mutation Positive Recurrent Non–Small Cell Lung Cancer (NSCLC; SWOG S1507, NCT-02642042)
Open the PDF for Phase II Study of Docetaxel and Trametinib in Patients with <em>KRAS</em> Mutation Positive Recurrent Non–Small Cell Lung Cancer (NSCLC; SWOG S1507, NCT-02642042) in another window
Includes: Supplementary data
Journal Articles

Circulating Tumor DNA Kinetics Predict Progression-Free and Overall Survival in EGFR TKI–Treated Patients with EGFR-Mutant NSCLC (SWOG S1403)

Philip C. Mack, Jieling Miao, Mary W. Redman, James Moon, Sarah B. Goldberg, Roy S. Herbst, Mary Ann Melnick, Zenta Walther, Fred R. Hirsch, Katerina Politi, Karen Kelly, David R. Gandara
Journal: Clinical Cancer Research
Clin Cancer Res (2022) 28 (17): 3752–3760.
https://doi.org/10.1158/1078-0432.CCR-22-0741
Published: 01 September 2022
View article titled, Circulating Tumor DNA Kinetics Predict Progression-Free and Overall Survival in EGFR TKI–Treated Patients with <em>EGFR</em>-Mutant NSCLC (SWOG S1403)
Open the PDF for Circulating Tumor DNA Kinetics Predict Progression-Free and Overall Survival in EGFR TKI–Treated Patients with <em>EGFR</em>-Mutant NSCLC (SWOG S1403) in another window
Includes: Supplementary data
Journal Articles

The Landscape of Actionable Genomic Alterations in Cell-Free Circulating Tumor DNA from 21,807 Advanced Cancer Patients

Oliver A. Zill, Kimberly C. Banks, Stephen R. Fairclough, Stefanie A. Mortimer, James V. Vowles, Reza Mokhtari, David R. Gandara, Philip C. Mack, Justin I. Odegaard, Rebecca J. Nagy, Arthur M. Baca, Helmy Eltoukhy, Darya I. Chudova, Richard B. Lanman, AmirAli Talasaz
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2018) 24 (15): 3528–3538.
https://doi.org/10.1158/1078-0432.CCR-17-3837
Published: 31 July 2018
View article titled, The Landscape of Actionable Genomic Alterations in Cell-Free Circulating Tumor DNA from 21,807 Advanced Cancer Patients
Open the PDF for The Landscape of Actionable Genomic Alterations in Cell-Free Circulating Tumor DNA from 21,807 Advanced Cancer Patients in another window
Includes: Supplementary data
Journal Articles

Efficacy of the PARP Inhibitor Veliparib with Carboplatin or as a Single Agent in Patients with Germline BRCA1- or BRCA2-Associated Metastatic Breast Cancer: California Cancer Consortium Trial NCT01149083

George Somlo, Paul H. Frankel, Banu K. Arun, Cynthia X. Ma, Agustin A. Garcia, Tessa Cigler, Leah V. Cream, Harold A. Harvey, Joseph A. Sparano, Rita Nanda, Helen K. Chew, Timothy J. Moynihan, Linda T. Vahdat, Matthew P. Goetz, Jan H. Beumer, Arti Hurria, Joanne Mortimer, Richard Piekarz, Sharon Sand, Josef Herzog, Lily R. Van Tongeren, Katherine V. Ferry-Galow, Alice P. Chen, Christopher Ruel, Edward M. Newman, David R. Gandara, Jeffrey N. Weitzel
Journal: Clinical Cancer Research
Clin Cancer Res (2017) 23 (15): 4066–4076.
https://doi.org/10.1158/1078-0432.CCR-16-2714
Published: 01 August 2017
View article titled, Efficacy of the PARP Inhibitor Veliparib with Carboplatin or as a Single Agent in Patients with Germline <em>BRCA1</em>- or <em>BRCA2</em>-Associated Metastatic Breast Cancer: California Cancer Consortium Trial NCT01149083
Open the PDF for Efficacy of the PARP Inhibitor Veliparib with Carboplatin or as a Single Agent in Patients with Germline <em>BRCA1</em>- or <em>BRCA2</em>-Associated Metastatic Breast Cancer: California Cancer Consortium Trial NCT01149083 in another window
Includes: Supplementary data
Journal Articles

ALCHEMIST Trials: A Golden Opportunity to Transform Outcomes in Early-Stage Non–Small Cell Lung Cancer

Ramaswamy Govindan, Sumithra J. Mandrekar, David E. Gerber, Geoffrey R. Oxnard, Suzanne E. Dahlberg, Jamie Chaft, Shakun Malik, Margaret Mooney, Jeffrey S. Abrams, Pasi A. Jänne, David R. Gandara, Suresh S. Ramalingam, Everett E. Vokes
Journal: Clinical Cancer Research
Clin Cancer Res (2015) 21 (24): 5439–5444.
https://doi.org/10.1158/1078-0432.CCR-15-0354
Published: 14 December 2015
View article titled, ALCHEMIST Trials: A Golden Opportunity to Transform Outcomes in Early-Stage Non–Small Cell Lung Cancer
Open the PDF for ALCHEMIST Trials: A Golden Opportunity to Transform Outcomes in Early-Stage Non–Small Cell Lung Cancer in another window
Journal Articles

Phase II Study of the AKT Inhibitor MK-2206 plus Erlotinib in Patients with Advanced Non–Small Cell Lung Cancer Who Previously Progressed on Erlotinib

Primo N. Lara, Jr, Jeff Longmate, Philip C. Mack, Karen Kelly, Mark A. Socinski, Ravi Salgia, Barbara Gitlitz, Tianhong Li, Mariana Koczywas, Karen L. Reckamp, David R. Gandara
Journal: Clinical Cancer Research
Clin Cancer Res (2015) 21 (19): 4321–4326.
https://doi.org/10.1158/1078-0432.CCR-14-3281
Published: 30 September 2015
View article titled, Phase II Study of the AKT Inhibitor MK-2206 plus Erlotinib in Patients with Advanced Non–Small Cell Lung Cancer Who Previously Progressed on Erlotinib
Open the PDF for Phase II Study of the AKT Inhibitor MK-2206 plus Erlotinib in Patients with Advanced Non–Small Cell Lung Cancer Who Previously Progressed on Erlotinib in another window
Journal Articles

Phase I Trial of Arginine Deprivation Therapy with ADI-PEG 20 Plus Docetaxel in Patients with Advanced Malignant Solid Tumors

Benjamin K. Tomlinson, James A. Thomson, John S. Bomalaski, Monica Diaz, Taiwo Akande, Nichole Mahaffey, Tianhong Li, Mrinal P. Dutia, Karen Kelly, I-Yeh Gong, Thomas Semrad, David R. Gandara, Chong-Xian Pan, Primo N. Lara, Jr
Journal: Clinical Cancer Research
Clin Cancer Res (2015) 21 (11): 2480–2486.
https://doi.org/10.1158/1078-0432.CCR-14-2610
Published: 31 May 2015
View article titled, Phase I Trial of Arginine Deprivation Therapy with ADI-PEG 20 Plus Docetaxel in Patients with Advanced Malignant Solid Tumors
Open the PDF for Phase I Trial of Arginine Deprivation Therapy with ADI-PEG 20 Plus Docetaxel in Patients with Advanced Malignant Solid Tumors in another window
Includes: Supplementary data
Journal Articles

Squamous Cell Lung Cancer: From Tumor Genomics to Cancer Therapeutics

David R. Gandara, Peter S. Hammerman, Martin L. Sos, Primo N. Lara, Jr, Fred R. Hirsch
Journal: Clinical Cancer Research
Clin Cancer Res (2015) 21 (10): 2236–2243.
https://doi.org/10.1158/1078-0432.CCR-14-3039
Published: 14 May 2015
View article titled, Squamous Cell Lung Cancer: From Tumor Genomics to Cancer Therapeutics
Open the PDF for Squamous Cell Lung Cancer: From Tumor Genomics to Cancer Therapeutics in another window
Journal Articles

Randomized Trial of Oral Cyclophosphamide and Veliparib in High-Grade Serous Ovarian, Primary Peritoneal, or Fallopian Tube Cancers, or BRCA-Mutant Ovarian Cancer

Shivaani Kummar, Amit M. Oza, Gini F. Fleming, Daniel M. Sullivan, David R. Gandara, Michael J. Naughton, Miguel A. Villalona-Calero, Robert J. Morgan, Jr, Peter M. Szabo, Ahrim Youn, Alice P. Chen, Jiuping Ji, Deborah E. Allen, Chih-Jian Lih, Michele G. Mehaffey, William D. Walsh, Paul M. McGregor, III, Seth M. Steinberg, P. Mickey Williams, Robert J. Kinders, Barbara A. Conley, Richard M. Simon, James H. Doroshow
Journal: Clinical Cancer Research
Clin Cancer Res (2015) 21 (7): 1574–1582.
https://doi.org/10.1158/1078-0432.CCR-14-2565
Published: 31 March 2015
View article titled, Randomized Trial of Oral Cyclophosphamide and Veliparib in High-Grade Serous Ovarian, Primary Peritoneal, or Fallopian Tube Cancers, or <em>BRCA</em>-Mutant Ovarian Cancer
Open the PDF for Randomized Trial of Oral Cyclophosphamide and Veliparib in High-Grade Serous Ovarian, Primary Peritoneal, or Fallopian Tube Cancers, or <em>BRCA</em>-Mutant Ovarian Cancer in another window
Includes: Supplementary data
Journal Articles

Lung Master Protocol (Lung-MAP)—A Biomarker-Driven Protocol for Accelerating Development of Therapies for Squamous Cell Lung Cancer: SWOG S1400

Roy S. Herbst, David R. Gandara, Fred R. Hirsch, Mary W. Redman, Michael LeBlanc, Philip C. Mack, Lawrence H. Schwartz, Everett Vokes, Suresh S. Ramalingam, Jeffrey D. Bradley, Dana Sparks, Yang Zhou, Crystal Miwa, Vincent A. Miller, Roman Yelensky, Yali Li, Jeff D. Allen, Ellen V. Sigal, David Wholley, Caroline C. Sigman, Gideon M. Blumenthal, Shakun Malik, Gary J. Kelloff, Jeffrey S. Abrams, Charles D. Blanke, Vassiliki A. Papadimitrakopoulou
Journal: Clinical Cancer Research
Clin Cancer Res (2015) 21 (7): 1514–1524.
https://doi.org/10.1158/1078-0432.CCR-13-3473
Published: 31 March 2015
View article titled, Lung Master Protocol (Lung-MAP)—A Biomarker-Driven Protocol for Accelerating Development of Therapies for Squamous Cell Lung Cancer: SWOG S1400
Open the PDF for Lung Master Protocol (Lung-MAP)—A Biomarker-Driven Protocol for Accelerating Development of Therapies for Squamous Cell Lung Cancer: SWOG S1400 in another window
Journal Articles

Antitumor Activity in RAS-Driven Tumors by Blocking AKT and MEK

Anthony W. Tolcher, Khurum Khan, Michael Ong, Udai Banerji, Vassiliki Papadimitrakopoulou, David R. Gandara, Amita Patnaik, Richard D. Baird, David Olmos, Christopher R. Garrett, Jeffrey M. Skolnik, Eric H. Rubin, Paul D. Smith, Pearl Huang, Maria Learoyd, Keith A. Shannon, Anne Morosky, Ernestina Tetteh, Ying-Ming Jou, Kyriakos P. Papadopoulos, Victor Moreno, Brianne Kaiser, Timothy A. Yap, Li Yan, Johann S. de Bono
Journal: Clinical Cancer Research
Clin Cancer Res (2015) 21 (4): 739–748.
https://doi.org/10.1158/1078-0432.CCR-14-1901
Published: 16 February 2015
View article titled, Antitumor Activity in <em>RAS</em>-Driven Tumors by Blocking AKT and MEK
Open the PDF for Antitumor Activity in <em>RAS</em>-Driven Tumors by Blocking AKT and MEK in another window
Includes: Supplementary data
Journal Articles

Abstract IA20: Linking tumor genomics to patient outcomes through a large-scale patient-derived xenograft (PDX) platform.

David R. Gandara, T. Li, P.N. Lara, K. Kelly, D.T. Cooke, R. Gandour-Edwards, K. Yoneda, N. Goodwin, S. Kuslak-Meyer, P. Mack
Journal: Clinical Cancer Research
Clin Cancer Res (2014) 20 (2_Supplement): IA20.
https://doi.org/10.1158/1078-0432.14AACRIASLC-IA20
Published: 16 January 2014
View article titled, Abstract IA20: Linking tumor genomics to patient outcomes through a large-scale patient-derived xenograft (PDX) platform.
Journal Articles

Design of a Phase III Clinical Trial with Prospective Biomarker Validation: SWOG S0819

Mary W. Redman, John J. Crowley, Roy S. Herbst, Fred R. Hirsch, David R. Gandara
Journal: Clinical Cancer Research
Clin Cancer Res (2012) 18 (15): 4004–4012.
https://doi.org/10.1158/1078-0432.CCR-12-0167
Published: 30 July 2012
View article titled, Design of a Phase III Clinical Trial with Prospective Biomarker Validation: SWOG S0819
Open the PDF for Design of a Phase III Clinical Trial with Prospective Biomarker Validation: SWOG S0819 in another window
Includes: Supplementary data
Journal Articles

A Phase I Study of Veliparib in Combination with Metronomic Cyclophosphamide in Adults with Refractory Solid Tumors and Lymphomas

Shivaani Kummar, Jiuping Ji, Robert Morgan, Heinz-Josef Lenz, Shannon L. Puhalla, Chandra P. Belani, David R. Gandara, Deborah Allen, Brian Kiesel, Jan H. Beumer, Edward M. Newman, Larry Rubinstein, Alice Chen, Yiping Zhang, Lihua Wang, Robert J. Kinders, Ralph E. Parchment, Joseph E. Tomaszewski, James H. Doroshow
Journal: Clinical Cancer Research
Clin Cancer Res (2012) 18 (6): 1726–1734.
https://doi.org/10.1158/1078-0432.CCR-11-2821
Published: 14 March 2012
View article titled, A Phase I Study of Veliparib in Combination with Metronomic Cyclophosphamide in Adults with Refractory Solid Tumors and Lymphomas
Open the PDF for A Phase I Study of Veliparib in Combination with Metronomic Cyclophosphamide in Adults with Refractory Solid Tumors and Lymphomas in another window
Includes: Supplementary data
Journal Articles

Aflibercept (VEGF Trap) in Inoperable Stage III or Stage IV Melanoma of Cutaneous or Uveal Origin

Ahmad A. Tarhini, Paul Frankel, Kim A. Margolin, Scott Christensen, Christopher Ruel, Janice Shipe-Spotloe, David R. Gandara, Alice Chen, John M. Kirkwood
Journal: Clinical Cancer Research
Clin Cancer Res (2011) 17 (20): 6574–6581.
https://doi.org/10.1158/1078-0432.CCR-11-1463
Published: 14 October 2011
View article titled, Aflibercept (VEGF Trap) in Inoperable Stage III or Stage IV Melanoma of Cutaneous or Uveal Origin
Open the PDF for Aflibercept (VEGF Trap) in Inoperable Stage III or Stage IV Melanoma of Cutaneous or Uveal Origin in another window
Includes: Supplementary data
Journal Articles

The Tissue Is the Issue: Personalized Medicine for Non-Small Cell Lung Cancer

Fred R. Hirsch, Murry W. Wynes, David R. Gandara, Paul A. Bunn, Jr.
Journal: Clinical Cancer Research
Clin Cancer Res (2010) 16 (20): 4909–4911.
https://doi.org/10.1158/1078-0432.CCR-10-2005
Published: 13 October 2010
View article titled, The Tissue Is the Issue: Personalized Medicine for Non-Small Cell Lung Cancer
Open the PDF for The Tissue Is the Issue: Personalized Medicine for Non-Small Cell Lung Cancer in another window
Includes: Supplementary data
Journal Articles

A Phase II Trial of Vorinostat (Suberoylanilide Hydroxamic Acid) in Metastatic Breast Cancer: A California Cancer Consortium Study

Thehang H. Luu, Robert J. Morgan, Lucille Leong, Dean Lim, Mark McNamara, Jana Portnow, Paul Frankel, David D. Smith, James H. Doroshow, David R. Gandara, Ana Aparicio, George Somlo, Carol Wong
Journal: Clinical Cancer Research
Clin Cancer Res (2008) 14 (21): 7138–7142.
https://doi.org/10.1158/1078-0432.CCR-08-0122
Published: 03 November 2008
View article titled, A Phase II Trial of Vorinostat (Suberoylanilide Hydroxamic Acid) in Metastatic Breast Cancer: A California Cancer Consortium Study
Open the PDF for A Phase II Trial of Vorinostat (Suberoylanilide Hydroxamic Acid) in Metastatic Breast Cancer: A California Cancer Consortium Study in another window
Journal Articles

A Multigene Assay Is Prognostic of Survival in Patients with Early-Stage Lung Adenocarcinoma

Dan J. Raz, M. Roshni Ray, Jae Y. Kim, Biao He, Miquel Taron, Marcin Skrzypski, Mark Segal, David R. Gandara, Rafael Rosell, David M. Jablons
Journal: Clinical Cancer Research
Clin Cancer Res (2008) 14 (17): 5565–5570.
https://doi.org/10.1158/1078-0432.CCR-08-0544
Published: 02 September 2008
View article titled, A Multigene Assay Is Prognostic of Survival in Patients with Early-Stage Lung Adenocarcinoma
Open the PDF for A Multigene Assay Is Prognostic of Survival in Patients with Early-Stage Lung Adenocarcinoma in another window
Includes: Supplementary data
Journal Articles

Aurora Kinases as Anticancer Drug Targets

Oliver Gautschi, Jim Heighway, Philip C. Mack, Phillip R. Purnell, Primo N. Lara, Jr., David R. Gandara
Journal: Clinical Cancer Research
Clin Cancer Res (2008) 14 (6): 1639–1648.
https://doi.org/10.1158/1078-0432.CCR-07-2179
Published: 17 March 2008
View article titled, Aurora Kinases as Anticancer Drug Targets
Open the PDF for Aurora Kinases as Anticancer Drug Targets in another window
Journal Articles

Incorporating Bortezomib into the Treatment of Lung Cancer

Angela M. Davies, Primo N. Lara, Jr., Philip C. Mack, David R. Gandara
Journal: Clinical Cancer Research
Clin Cancer Res (2007) 13 (15): 4647s–4651s.
https://doi.org/10.1158/1078-0432.CCR-07-0334
Published: 01 August 2007
View article titled, Incorporating Bortezomib into the Treatment of Lung Cancer
Open the PDF for Incorporating Bortezomib into the Treatment of Lung Cancer in another window